High tierMendelian RandomizationCitation verified
Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis
Brian A Ference, Wonsuk Yoo, Issa Alesh, John M Flack - Journal of the American College of Cardiology, 2012
Using nine genetic variants as a proxy for lifelong lower LDL, the study found that long-term exposure to lower LDL beginning early in life was associated with roughly a 54.5% lower risk of coronary heart disease per 1 mmol/L - about three times the per-unit benefit seen when statins are started later in life.
Key findings
- All 9 polymorphisms showed a highly consistent reduction in CHD risk per unit lower LDL-C, with no heterogeneity (I2 = 0.0%).
- 54.5% (95% CI 48.8-59.5) lower CHD risk per 1 mmol/L lifelong lower LDL-C.
- About a three-fold greater per-unit reduction than statins started later, implying cumulative exposure (duration) matters, not just level.
Effect measures
- Relative Risk Reduction: 54.5% lower CHD risk per 1 mmol/L (38.7 mg/dL) lower LDL-C95% CI 48.8% to 59.5%
Why this evidence tier (High)
- Risk of bias:
- Mendelian randomization reduces confounding and reverse causation by using randomly-allocated genotypes.
- Precision:
- Large combined sample (312k) and zero heterogeneity across instruments give high precision.
- Directness:
- Directly estimates the effect of lifelong lower LDL on CHD - though genetic lifelong exposure differs from a drug started in mid-life (canalization).
- Consistency:
- Strikingly consistent across nine independent variants.
- Funding / COI:
- See source disclosures.
High certainty for the causality inference; the main caveat is that lifelong genetic exposure is not the same as later pharmacologic lowering.
- Population:
- Pooled genetic-association data; primary combined analysis of 312,321 participants across prospective cohort and case-control studies.
- Conflicts of interest:
- Not reported on the fetched abstract; see full paper for disclosures.
- Funding:
- Not reported on the fetched abstract.
Limitations
- MR limitations: potential pleiotropy, weak-instrument bias, predominantly European-ancestry samples.
- Lifelong genetic exposure (canalization) is not directly comparable to drug therapy started later in life.